Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps
OncoTargets and Therapy · 2026-11 · Volume 19 · 1-18
DOI: 10.2147/ott.s653346 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift OncoTargets and Therapy, 2026-11. Verfasst von Qi Qi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
- Department of Oncology Medicine, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Zitieren
APA
Qi, Q., Han, B., & Fu, R. (2026). Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps. OncoTargets and Therapy, Volume 19, 1-18. https://doi.org/10.2147/ott.s653346
Vancouver
Qi Q, Han B, Fu R. Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps. OncoTargets and Therapy. 2026;Volume 19:1-18. doi:10.2147/ott.s653346
BibTeX
@article{Qi2026,
author = {Qi, Qi and Han, Bing and Fu, Runshi},
title = {Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps},
journal = {OncoTargets and Therapy},
year = {2026},
volume = {Volume 19},
pages = {1--18},
doi = {10.2147/ott.s653346}
}
EUVIMED